Trillium Asset Management LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 541.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 21,490 shares of the medical research company’s stock after acquiring an additional 18,139 shares during the period. Trillium Asset Management LLC’s holdings in IQVIA were worth $5,778,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of IQVIA in the second quarter valued at $2,811,292,000. Canada Pension Plan Investment Board purchased a new position in IQVIA during the second quarter worth about $240,911,000. Bank of America Corp DE purchased a new position in IQVIA during the second quarter worth about $235,551,000. Legal & General Group Plc purchased a new position in IQVIA during the second quarter worth about $211,342,000. Finally, Bank of New York Mellon Corp acquired a new stake in IQVIA in the 2nd quarter worth about $180,296,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Insider Transactions at IQVIA
In related news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the transaction, the insider owned 24,989 shares in the company, valued at $6,967,682.87. The trade was a 15.10% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several analysts have commented on IQV shares. Morgan Stanley lifted their price target on IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. UBS Group began coverage on shares of IQVIA in a research report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 target price on the stock. Robert W. Baird boosted their target price on shares of IQVIA from $324.00 to $328.00 and gave the company an “outperform” rating in a report on Tuesday, October 27th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Stifel Nicolaus upped their price target on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.21.
View Our Latest Stock Report on IQVIA
IQVIA Trading Down 2.1%
IQV stock traded down $5.67 during trading on Friday, reaching $265.44. 1,986,072 shares of the stock traded hands, compared to its average volume of 1,407,100. The business’s 50 day moving average price is $267.55 and its 200-day moving average price is $211.88. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The firm has a market capitalization of $43.74 billion, a PE ratio of 32.25, a P/E/G ratio of 2.41 and a beta of 1.16.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The firm’s revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.00 earnings per share. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.
About IQVIA
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Further Reading
- Five stocks we like better than IQVIA
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
